Tango Therapeutics (TNGX) Income towards Parent Company (2020 - 2025)
Tango Therapeutics has reported Income towards Parent Company over the past 6 years, most recently at -$38.7 million for Q4 2025.
- Quarterly results put Income towards Parent Company at -$38.7 million for Q4 2025, down 2.86% from a year ago — trailing twelve months through Dec 2025 was -$101.6 million (up 22.03% YoY), and the annual figure for FY2025 was -$101.6 million, up 22.03%.
- Income towards Parent Company for Q4 2025 was -$38.7 million at Tango Therapeutics, down from $15.9 million in the prior quarter.
- Over the last five years, Income towards Parent Company for TNGX hit a ceiling of $15.9 million in Q3 2025 and a floor of -$39.9 million in Q1 2025.
- Median Income towards Parent Company over the past 5 years was -$26.8 million (2023), compared with a mean of -$25.0 million.
- Biggest five-year swings in Income towards Parent Company: tumbled 951806.78% in 2021 and later surged 154.46% in 2025.
- Tango Therapeutics' Income towards Parent Company stood at -$22.1 million in 2021, then tumbled by 31.77% to -$29.1 million in 2022, then fell by 5.82% to -$30.8 million in 2023, then fell by 22.5% to -$37.7 million in 2024, then decreased by 2.86% to -$38.7 million in 2025.
- The last three reported values for Income towards Parent Company were -$38.7 million (Q4 2025), $15.9 million (Q3 2025), and -$38.9 million (Q2 2025) per Business Quant data.